Red blood cell transfusions in very and extremely low birthweight infants under restrictive transfusion guidelines: is exogenous erythropoietin necessary?

A R Franz, F Pohlandt

Abstract

Objective—To examine the number and volume of red blood cell transfusions (RBCTs) in very and extremely low birthweight infants under restrictive red blood cell transfusion guidelines without erythropoietin administration, and to compare the results with those reported in similar infants receiving erythropoietin.

Methods—From April 1996 to June 1999, all RBCTs given to infants with a birth weight of less than 1500 g were prospectively recorded. Data on RBCT combined with erythropoietin treatment and RBCT guidelines were extracted from four prospective randomised trials of erythropoietin for anaemia of prematurity.

Results—When the restrictive RBCT guidelines were followed, the number of RBCTs and volume transfused were similar to those reported during erythropoietin administration.

Conclusions—RBCT guidelines may have a similar impact on RBCT in very low birthweight infants to the administration of erythropoietin. The effect of RBCT guidelines on RBCT frequency should be considered when evaluating the efficacy of erythropoietin administration to preterm infants.

Keywords: preterm; red blood cell; erythrocyte; packed cell volume; transfusion; erythropoietin

Red blood cell transfusions (RBCTs) are often given to very low birthweight infants, and 50–80% of these infants receive multiple RBCTs during their initial hospital stay.1–3 The effects of RBCT on outcome measures such as apnoea, weight gain, heart rate, and oxygen consumption have been studied in a few small randomised, mostly uncontrolled, trials and several observational studies, with controversial results (reviewed in4). In the absence of uniformly accepted physiological or evidence based RBCT criteria, RBCT practices vary greatly between neonatal units,5 6 but, at least at first glance, these variations do not seem to result in different outcomes.5 6

Reducing the number of RBCTs reduces the risk of transmission of cytomegalovirus, hepatitis virus, and HIV, and may reduce costs. As frequent RBCT may be associated with retinopathy of prematurity7 8 and bronchopulmonary dysplasia,9 10 reducing the number of RBCTs may be even more important.

Erythropoietin therapy for prevention and treatment of anaemia of prematurity is still not generally recommended,11 although it has been shown to effectively stimulate erythropoiesis in vitro12 13 and in vivo,14 15 and was shown to be effective in reducing the need for transfusion in various age groups of preterm infants.14 15 16 17 18 19 20

Studies have been criticised for examining relatively large preterm infants or those in a stable condition, or for giving transfusions to maintain packed cell volume at unusually high levels, thereby showing an effect of erythropoietin in infants who may not need to be transfused at all.11 21 As most erythropoietin trials indeed used relatively liberal RBCT guidelines, it remains unclear whether erythropoietin administration would result in a clinically relevant reduction in the number of RBCTs to very low birthweight infants if restrictive RBCT guidelines were followed.

To gain a better understanding of whether it would be appropriate to start erythropoietin treatment in our centre, we prospectively documented all RBCTs given to our very low birthweight infants during a three year period. The aim of this study was to evaluate our RBCT practice and to compare the effect of restrictive transfusion guidelines on RBCT with the effect of erythropoietin as reported in the literature.

Methods

This study served as a surveillance of our current treatment regimen and did not require approval of our ethics committee or parental consent.

Patients

All infants with a birth weight of less than 1500 g, born between April 1996 and June 1999 in our level 3 neonatal referral centre, were considered. To match the study population of the erythropoietin trials, infants with major anomalies, haemolytic disease, and twin to twin transfusion syndrome were excluded.

Data Collection

Between April 1996 and June 1999, all RBCTs to infants born at our centre with a birth weight of less than 1500 g were prospectively recorded. The data were compared with those recorded at the local blood bank to ensure completeness.
Further indications for transfusions in Ulm at a packed cell volume of <0.40 were: presence of cyanotic heart disease, septic shock, major surgery, and age <1 week.

Maier et al\textsuperscript{27} Pcv <0.40 or Hgb <140 g/l or blood loss >9 ml/kg

Maier et al\textsuperscript{27} Fio\textsubscript{2} >0.40 or <2 weeks of age

Shannon et al\textsuperscript{22} MAP \geq 6

Shannon et al\textsuperscript{22} MAP < 6

Ohls et al\textsuperscript{20} Pcv <0.33

Ohls et al\textsuperscript{20} Fio\textsubscript{2} >0.35

Ohls et al\textsuperscript{20} Fio\textsubscript{2} <0.22–0.35 or SoA present

Maier et al\textsuperscript{27} Pcv <0.33

Maier et al\textsuperscript{27} Fio\textsubscript{2} >0.40

Maier et al\textsuperscript{27} Fio\textsubscript{2} <0.40 and <2 weeks of age

Maier et al\textsuperscript{27} Fio\textsubscript{2} <0.40 and <2 weeks of age

Maier et al\textsuperscript{27} Fio\textsubscript{2} <0.25

Ulm Fio\textsubscript{2} >0.25

Ulm Fio\textsubscript{2} <0.25

Pcv, venous centrifuged packed cell volume; Hgb, haemoglobin concentration; Fio\textsubscript{2}, fraction of inspired oxygen; SoA, signs of anaemia; MAP, mean airway pressure.

### Birth weight and gestational age

Birth weight and gestational age of the infant were recorded together with indication for each RBCT and volume transfused.

### RBCT GUIDELINES

Restrictive RBCT guidelines were implemented (table 1). At any indication, RBCTs were given to achieve a packed cell volume of 0.45–0.50, and were usually administered in two to three fractions over 24 hours. Leucocyte depleted packed erythrocytes from cytomegalovirus seronegative donors were used. Packed erythrocytes were reconstituted to a packed cell volume of 0.55–0.60. Each unit was divided into four satellite bags allocated to one infant, stored for a shelf life of 14 days, and irradiated just before transfusion.

### GENERAL TREATMENT GUIDELINES

Infants were fed human breast milk enriched in protein and energy (without iron supplementation) or iron supplemented preterm infant formula (12 mg iron/l). The aim was to achieve a protein intake of 3–3.5 g/kg/day and an energy intake of 500–550 kJ/kg/day. Infants received enteral iron supplementation of 2–6 mg/kg/day according to a protocol of a trial on iron supplementation.\textsuperscript{24}

### RBCT COMBINED WITH ERYTHROPOIETIN ADMINISTRATION

The RBCT data and RBCT guidelines were extracted from four prospective randomised trials of erythropoietin for the prevention and treatment of anaemia of prematurity.\textsuperscript{19, 20, 22, 25} Only randomised trials including ventilated infants were selected because more than 70% of RBCTs at our institution are given to infants on mechanical ventilation. With the exception of the study of Ohls and coworkers,\textsuperscript{20} which specifically looked at the role of erythropoietin in infants with a birth weight of less than 750 g, trials with less than 100 patients were excluded.

### COMPARISON OF RBCT FREQUENCY

For comparison with the selected erythropoietin trials, the subgroups of infants born at Ulm who would have been eligible for each erythropoietin trial according to the trial’s inclusion criteria and who completed the study period of the respective erythropoietin trial at our centre were analysed. The number of RBCTs given to these subgroups and the volume transfused during the respective study period were compared with the RBCT data extracted from each erythropoietin trial.

### Results

During the study period, 421 very low birthweight infants were born in our institution. Eight infants were excluded because of incomplete data collection, five had major anomalies, and eight suffered from haemolytic disease or twin-twin transfusion syndrome. This left 400 infants who were evaluated. The mean birth weight was 953 g (median 940 g, range 300–1500 g), and mean gestational age was 27 weeks and 5 days (median 27 weeks, range 22–38 weeks). Of these 400 infants, 20 died between day 1 and 287, and 172 were referred to other hospitals for continuing care between day 2 and 69.

A total of 569 transfusions were given to the 400 patients evaluated, with an average of 26 ml/kg/RBCT. Almost half (190 infants; 47.5%) never received a RBCT. Of these, nine had a birth weight below 750 g, 51 a birth weight of 751–1000 g, and 130 a birth weight of 1001–1499 g. A total of 407 RBCTs (71.5%) were given during mechanical ventilation at a mean packed cell volume of 0.34, and 332 RBCTs (58.3%) were given during the first two weeks of life. Nineteen RBCTs were given because the packed cell volume dropped below 0.21 in asymptomatic infants at a mean age of 40 days. Nineteen RBCTs were given not following the guidelines.

Table 1 gives the RBCT guidelines for the selected erythropoietin trials.

For comparison with the second European Multicenter Erythropoietin Trial,\textsuperscript{19, 20} 180 infants with a birth weight of 750–1499 g who met the inclusion criteria of the trial and who were treated for at least 42 days at our institution were analysed. Patient characteristics were

<table>
<thead>
<tr>
<th>Study</th>
<th>Pcv or Hgb</th>
<th>SoA</th>
<th>Pcv or Hgb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maier et al\textsuperscript{27}</td>
<td>Pcv &lt;0.40 or Hgb &lt;140 g/l or blood loss &gt;9 ml/kg</td>
<td>Fio\textsubscript{2} &gt;0.40 or &lt;2 weeks of age</td>
<td>Fio\textsubscript{2} &lt;0.40 or blood loss &gt;9 ml/kg</td>
</tr>
<tr>
<td>Shannon et al\textsuperscript{22}</td>
<td>MAP \geq 6</td>
<td>Pcv &lt;0.36</td>
<td>Pcv &lt;0.36</td>
</tr>
<tr>
<td>Shannon et al\textsuperscript{22}</td>
<td>MAP &lt; 6</td>
<td>Pcv &lt;0.31</td>
<td>Pcv &lt;0.31</td>
</tr>
<tr>
<td>Ohls et al\textsuperscript{20}</td>
<td>Pcv &lt;0.33</td>
<td>SoA present</td>
<td>Pcv &lt;0.28</td>
</tr>
<tr>
<td>Ohls et al\textsuperscript{20}</td>
<td>Fio\textsubscript{2} &gt;0.35</td>
<td>Pcv &lt;0.40</td>
<td>Pcv &lt;0.25</td>
</tr>
<tr>
<td>Ohls et al\textsuperscript{20}</td>
<td>Fio\textsubscript{2} &lt;0.22–0.35 or SoA present</td>
<td>Pcv &lt;0.35</td>
<td>Pcv &lt;0.30</td>
</tr>
<tr>
<td>Maier et al\textsuperscript{27}</td>
<td>Pcv &lt;0.33</td>
<td>SoA present</td>
<td>Pcv &lt;0.28</td>
</tr>
<tr>
<td>Maier et al\textsuperscript{27}</td>
<td>Fio\textsubscript{2} &gt;0.40</td>
<td>Pcv &lt;0.40</td>
<td>Pcv &lt;0.25</td>
</tr>
<tr>
<td>Maier et al\textsuperscript{27}</td>
<td>Fio\textsubscript{2} &lt;0.40 and &lt;2 weeks of age</td>
<td>Pcv &lt;0.35</td>
<td>Pcv &lt;0.30</td>
</tr>
<tr>
<td>Maier et al\textsuperscript{27}</td>
<td>Fio\textsubscript{2} &lt;0.40 and &lt;2 weeks of age</td>
<td>Pcv &lt;0.25</td>
<td>Pcv &lt;0.25</td>
</tr>
<tr>
<td>Ulm</td>
<td>Fio\textsubscript{2} &gt;0.25</td>
<td>Fio\textsubscript{2} &lt;0.25</td>
<td>Fio\textsubscript{2} &lt;0.30</td>
</tr>
</tbody>
</table>
similar, with a higher proportion of extremely low birthweight infants in our patients (table 2). The number of RBCT-free patients and the

Table 2 Red blood cell transfusion practices: comparison with the 2nd European Multicenter Trial of EPO

<table>
<thead>
<tr>
<th></th>
<th>EPO trial</th>
<th>750 IU EPO/week</th>
<th>No EPO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>180</td>
<td>120</td>
<td>121</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>1100 (930;1260)</td>
<td>1110 (1040;1370)</td>
<td>1150 (983;1310)</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>29 (27;30)</td>
<td>29 (27;31)</td>
<td>29 (27;30)</td>
</tr>
<tr>
<td>Gestational age &lt;38 weeks</td>
<td>119 (+60)</td>
<td>136 (+56)</td>
<td></td>
</tr>
<tr>
<td>Not transfused (day 3–42)</td>
<td>134 (+74)</td>
<td>60 (+50)</td>
<td>40 (+33)</td>
</tr>
<tr>
<td>Mean RBCT/infant</td>
<td>0.38</td>
<td>0.87</td>
<td>1.25</td>
</tr>
</tbody>
</table>

As appropriate, values are median (quartiles) or number (%).

EPO, Erythropoietin; RBCT, red blood cell transfusion.

Table 3 Red blood cell transfusion practices: comparison with the 3rd European Multicenter Trial of EPO

<table>
<thead>
<tr>
<th></th>
<th>EPO trial</th>
<th>1500 IU EPO/week</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>88</td>
<td>92</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>810 (710;900)</td>
<td>793 (678;890)</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>26 (25;27)</td>
<td>26 (25;27)</td>
</tr>
<tr>
<td>Gestational age &lt;28 weeks</td>
<td>77 (+88)</td>
<td>139 (+76)</td>
</tr>
<tr>
<td>Gestational age 26–29 weeks</td>
<td>11 (+13)</td>
<td>44 (+24)</td>
</tr>
<tr>
<td>Not transfused (after day 3)</td>
<td>31 (+35)</td>
<td>29 (+32)</td>
</tr>
<tr>
<td>Infants with 1 RBCT</td>
<td>21 (+24)</td>
<td>19 (+21)</td>
</tr>
<tr>
<td>Infants with 2 RBCT</td>
<td>18 (+20)</td>
<td>14 (+15)</td>
</tr>
<tr>
<td>Infants with 3 RBCT</td>
<td>8 (+9)</td>
<td>5 (+5)</td>
</tr>
<tr>
<td>Infants with &gt;3 RBCT</td>
<td>11 (+13)</td>
<td>22 (+24)</td>
</tr>
<tr>
<td>Volume transfused (ml/infant)</td>
<td>19.3 (0.33.6)</td>
<td>12.9 (0.22.0)</td>
</tr>
</tbody>
</table>

As appropriate, values are median (quartiles) or number (%).

EPO, Erythropoietin; RBCT, red blood cell transfusion.

Table 4 Red blood cell transfusion practices: comparison with the American Multicenter Trial of EPO in Infants < 1251 g

<table>
<thead>
<tr>
<th></th>
<th>EPO trial</th>
<th>750 IU EPO/week</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>140</td>
<td>77</td>
</tr>
<tr>
<td>Mean birth weight (g)</td>
<td>907</td>
<td>923</td>
</tr>
<tr>
<td>&lt;750 g</td>
<td>35 (28)</td>
<td>13 (17)</td>
</tr>
<tr>
<td>751–1000 g</td>
<td>54 (39)</td>
<td>39 (51)</td>
</tr>
<tr>
<td>1001–1250 g</td>
<td>51 (36)</td>
<td>25 (32)</td>
</tr>
<tr>
<td>Mean gestational age (weeks)</td>
<td>27.0</td>
<td>26.8</td>
</tr>
<tr>
<td>Not transfused*</td>
<td>72 (51)</td>
<td>33 (43)</td>
</tr>
<tr>
<td>Mean RBCT/infant*</td>
<td>0.964</td>
<td>1.1</td>
</tr>
<tr>
<td>Mean volume transfused* (ml/infant)</td>
<td>13.5</td>
<td>16.5</td>
</tr>
</tbody>
</table>

Where appropriate, values are number (%).

*During the observation period—that is, for 42 days after study entry in the Shannon trial and for days 7–64 at the Ulm centre.

EPO, Erythropoietin; RBCT, red blood cell transfusion.

Table 5 Red blood cell transfusion practices: comparison with the American Trial of Early EPO in Infants < 751 g

<table>
<thead>
<tr>
<th></th>
<th>EPO trial</th>
<th>750 IU EPO/week</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>66</td>
<td>15</td>
</tr>
<tr>
<td>Mean birth weight (g)</td>
<td>613</td>
<td>677</td>
</tr>
<tr>
<td>Mean gestational age (weeks)</td>
<td>25.3</td>
<td>24.3</td>
</tr>
<tr>
<td>Mean RBCT (RBCT/infant)</td>
<td>2.44</td>
<td>4.7</td>
</tr>
<tr>
<td>Mean volume transfused (ml/kg/infant)</td>
<td>71*</td>
<td>70*</td>
</tr>
<tr>
<td>Mean erythrocyte volume transfused (ml/kg/infant)</td>
<td>39*</td>
<td>54*</td>
</tr>
</tbody>
</table>

*Packed erythrocytes were reconstituted to different packed cell volumes (0.50–0.60 at Ulm, 0.75–0.80 at the American Centres).

EPO, Erythropoietin; RBCT, red blood cell transfusion.

Key messages

- Indications for RBCT in preterm infants are controversial
- RBCT to very low birthweight infants can be reduced to the rate reported during erythropoietin administration if restrictive transfusion guidelines are applied
- When evaluating trials of erythropoietin administration to reduce RBCT in preterm infants, the effect of the transfusion guidelines applied during these studies should be taken into account
- Trials on RBCT and erythropoietin administration should focus on long term neurodevelopmental outcome

mean number of RBCTs per patient were considerably lower at our institution (table 2).

For comparison with the third European Multicenter Erythropoietin Trial, all infants with a birth weight below 1251 g and a gestational age of less than 31 weeks were selected. As patients were enrolled into this trial on different days of life, it was impossible to match the observation period exactly. For the patients treated at our institution, all RBCTs during an observation period from day 7 to day 64 are reported (which is a longer period than the 42 day study period in the trial). Again patient characteristics and results were similar in erythropoietin treated patients and patients in our centre (table 3). However, if transfused, our patients received a higher total amount of packed red cells per transfusion.

According to the inclusion criteria of the American Multicenter Trial by Shannon et al, all infants with a birth weight below 1251 g and a gestational age of less than 31 weeks were selected. As patients were enrolled into this trial on different days of life, it was impossible to match the observation period exactly. For the patients treated at our institution, all RBCTs during an observation period from day 7 to day 64 are reported (which is a longer period than the 42 day study period in the trial). Again patient characteristics and results were similar in erythropoietin treated patients and patients in our centre (table 4).

For comparison with the erythropoietin trial of Ohls et al., all patients with a birth weight of less than 751 g who were treated in our centre until day 21 were selected. Again our patients were less frequently transfused; however, the mean gestational age was higher in our patients (table 5). After exclusion of patients with a gestational age of more than 26 weeks to match the mean gestational age in the trial of Ohls et al, the mean number of transfusions was 2.69/infant and the mean volume transfused was 78 ml/kg/infant. Whereas patients in Ulm and in this trial received similar volumes of RBCT, packed red cells were more concentrated in the American study centres (to a packed cell volume of 0.75–0.80).

Discussion

The results of this 3 year prospective observational study of RBCT practice indicate that a low number and low cumulative volume of RBCTs can be achieved in very low birthweight infants even without erythropoietin treatment. It has been shown previously...
that RBCT guidelines effectively reduce the number of RBCTs, but this is the first report to compare RBCT practice under RBCT guidelines with that during erythropoietin administration.

Apart from variations in RBCT guidelines, differences in antenatal corticosteroid treatment, initial morbidity, iron and protein supplementation, and, most importantly, phlebotomy losses probably occurred and influenced the need for RBCT. The observation that infants received fewer RBCTs at our institution than at the American centres despite similar RBCT guidelines suggests such differences in general care.

Most RBCT guidelines are based on thresholds of haemoglobin level or packed cell volume. However, haemoglobin level and packed cell volume correlate poorly with red cell mass, and may not be a good predictor of oxygen delivery and benefit from RBCT. Improvement of oxygen carrying capacity after RBCT in asymptomatic infants with haemoglobin levels of 110–130 g/l, and in oxygen dependent non-ventilated preterm infants with haemoglobin levels of 65–88 g/l, did not result in a change in oxygen consumption, indicating that oxygen delivery was adequate before transfusion. Furthermore, adequate adaptation of cardiac output effectively attenuated the effects of variations in packed cell volume on systemic oxygen carrying capacity in preterm infants. We therefore hypothesise that, as long as an infant is growing and asymptomatic at a low packed cell volume, his/her oxygen delivery is adequately maintained.

Reducing the number of RBCTs may result in a reduction in costs, risk of viral infection, and retinopathy of prematurity and other diseases thought to be caused by free radicals, but there is no evidence that this reduction by accepting low packed cell volumes in asymptomatic infants is safe and benefits the patient. The safety and efficacy of this approach can only be evaluated in a large study with long term neurodevelopmental follow up.

As a crude measure of overall outcome, mortality before discharge (including mortality at the affiliated hospitals) was 6% in the 400 infants evaluated in this study and 7.6% in all 421 patients born at our institution during this three year period, and was not increased compared with recently published outcome data (16% mortality in 4593 infants with a birth weight of less than 1500 g). We conclude that under restrictive transfusion guidelines with adequate protein and iron supplementation, RBCT can be reduced to the rate reported erythropoietin treatment. It is currently unclear which approach benefits preterm infants most, and both approaches may be regarded as experimental. Randomised controlled trials focusing on long term neurodevelopmental outcome are necessary to provide better evidence of efficacy and safety of RBCT practices. As long as the indications for RBCT are controversial, results of erythropoietin trials will remain inconclusive.

3 Arch J, Wedgwood JF. Optimizing the approach to anemia in the preterm infant: is there a role for erythropoietin therapy? J Perinatol 1997;17:276–82.
30 www.archdischild.com


